DK0643726T3 - Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei - Google Patents

Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei

Info

Publication number: DK0643726T3
Authority: DK; Denmark
Prior art keywords: human; protein; pct; compositions; cell response
Prior art date: 1992-05-26

Application number

DK93913627T

Other languages

English (en)

Inventor

Cornelis Joseph Maria Melief

Wybe Martin Kast

Original Assignee

Seed Capital Investments

Univ Leiden

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-26

Filing date

1993-05-18

Publication date

2000-03-20

1993-05-18 Application filed by Seed Capital Investments, Univ Leiden filed Critical Seed Capital Investments

2000-03-20 Application granted granted Critical

2000-03-20 Publication of DK0643726T3 publication Critical patent/DK0643726T3/da

Links

102100025064 Cellular tumor antigen p53 Human genes 0.000 title abstract 5
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
230000005867 T cell response Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 abstract 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000006698 induction Effects 0.000 abstract 1
230000002018 overexpression Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DK93913627T 1992-05-26 1993-05-18 Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei DK0643726T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP92201510		1992-05-26
PCT/NL1993/000102 WO1993024525A1 (en)	1992-05-26	1993-05-18	PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES

Publications (1)

Publication Number	Publication Date
DK0643726T3 true DK0643726T3 (da)	2000-03-20

Family

ID=8210629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93913627T DK0643726T3 (da)	1992-05-26	1993-05-18	Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei

Country Status (11)

Country	Link
US (1)	US5679641A (da)
EP (1)	EP0643726B1 (da)
JP (2)	JPH08501280A (da)
AT (1)	ATE183514T1 (da)
AU (1)	AU681853B2 (da)
CA (1)	CA2136624A1 (da)
DE (1)	DE69326064T2 (da)
DK (1)	DK0643726T3 (da)
ES (1)	ES2139012T3 (da)
GR (1)	GR3031919T3 (da)
WO (1)	WO1993024525A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0651653B1 (en) *	1992-07-22	2004-03-10	The Trustees Of Princeton University	p53 VACCINE
FR2698367B1 (fr) *	1992-11-02	1995-02-17	Eurobio Lab	Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
BR9406652A (pt) *	1993-03-05	1996-09-10	Cytel Corp	Composição
EP0726941B1 (en) *	1993-08-06	2002-04-03	Epimmune Inc.	Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
FR2722207B1 (fr) *	1994-07-07	1996-09-27	Inst Nat Sante Rech Med	Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
WO1996018409A1 (en)	1994-12-14	1996-06-20	The Scripps Research Institute	In vivo activation of tumor-specific cytotoxic t cells
US5925799A (en) *	1996-03-12	1999-07-20	Abb Lummus Global Inc.	Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
US6458354B1 (en)	1996-03-28	2002-10-01	The Johns Hopkins University	Molecular complexes which modify immune responses
NZ331688A (en) *	1996-03-28	2000-02-28	Univ Johns Hopkins	Soluble divalent and multivalent heterodimeric analogs of proteins
US6218363B1 (en) *	1996-08-28	2001-04-17	Thomas Jefferson University	MHC peptides and methods of use
SE9604581D0 (sv) *	1996-12-12	1996-12-12	Karolinska Innovations Ab	An agent against cancer and virus infections
US6268411B1 (en)	1997-09-11	2001-07-31	The Johns Hopkins University	Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
NZ506839A (en) *	1998-03-09	2003-05-30	Zealand Pharma As	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801695D0 (sv) *	1998-05-14	1998-05-14	Karolinska Innovations Ab	Inhibition of p53 function by a p53-derived peptide
DE69940774D1 (de) *	1998-06-17	2009-06-04	Idm Pharma Inc	Hla-bindende peptide und ihre verwendungen
CA2367692A1 (en) *	1999-03-15	2000-09-21	Introgen Therapeutics, Inc.	Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
TW410377B (en) *	1999-06-17	2000-11-01	Taiwan Semiconductor Mfg	Method of planarization and the apparatus of the same
CA2383737C (en) *	1999-09-08	2011-01-18	Transgene S.A.	Muc-1 derived peptides
FR2794368A1 (fr) *	1999-10-07	2000-12-08	Biovector Therapeutics	Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
CA2393662A1 (en) *	1999-12-10	2001-06-14	Epimmune Inc.	Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
AU7524601A (en) *	2000-06-05	2001-12-17	Sunol Molecular Corp	T cell receptor fusions and conjugates and methods of use thereof
DE10109855A1 (de) *	2001-03-01	2002-09-12	Stanislawski Thomas	Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
CA2487779C (en)	2001-06-05	2012-10-02	Altor Bioscience Corporation	P53 binding t cell receptor molecules and uses thereof
US7179784B2 (en) *	2001-07-10	2007-02-20	Massachusetts Institute Of Technology	Surfactant peptide nanostructures, and uses thereof
DE60334474D1 (de) *	2002-07-12	2010-11-18	Univ Johns Hopkins	Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
EP1888105A2 (en) *	2005-05-12	2008-02-20	Introgen Therapeutics, Inc.	P53 vaccines for the treatment of cancers
CA2662798A1 (en) *	2005-09-07	2007-03-15	Receptor Logic, Ltd.	Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2008021160A2 (en) *	2006-08-17	2008-02-21	Trustees Of Boston University	Regulation of litaf modulated cytokine production by a novel p53 short peptide
DK2118123T3 (da)	2007-01-31	2016-01-25	Dana Farber Cancer Inst Inc	Stabiliserede p53-peptider og anvendelser deraf
US8592377B2 (en)	2007-03-28	2013-11-26	President And Fellows Of Harvard College	Stitched polypeptides
ES2711526T3 (es)	2010-08-13	2019-05-06	Aileron Therapeutics Inc	Macrociclos peptidomiméticos
TW201806968A (zh)	2011-10-18	2018-03-01	艾利倫治療公司	擬肽巨環化合物
BR112014020103A2 (pt)	2012-02-15	2018-10-09	Aileron Therapeutics, Inc.	macrociclos peptidomiméticos
EP2819688A4 (en)	2012-02-15	2015-10-28	Aileron Therapeutics Inc	TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
WO2014071241A1 (en)	2012-11-01	2014-05-08	Aileron Therapeutics, Inc.	Disubstituted amino acids and methods of preparation and use thereof
EP3197478A4 (en)	2014-09-24	2018-05-30	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en)	2014-09-24	2020-05-14	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and formulations thereof
WO2016154058A1 (en)	2015-03-20	2016-09-29	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
WO2017044633A1 (en)	2015-09-10	2017-03-16	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles as modulators of mcl-1
SG11202002635RA (en) *	2017-09-29	2020-04-29	The United States Of America As Represented By The Secretary	Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
US11091522B2 (en)	2018-07-23	2021-08-17	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
US12453774B2 (en)	2019-11-07	2025-10-28	Genoimmune Therapeutics Co., Ltd.	Tumor immunotherapy polypeptide and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO312681B1 (no) *	1990-08-24	2002-06-17	Univ California	Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet

1993
- 1993-05-18 ES ES93913627T patent/ES2139012T3/es not_active Expired - Lifetime
- 1993-05-18 AT AT93913627T patent/ATE183514T1/de not_active IP Right Cessation
- 1993-05-18 US US08/338,634 patent/US5679641A/en not_active Expired - Fee Related
- 1993-05-18 EP EP93913627A patent/EP0643726B1/en not_active Expired - Lifetime
- 1993-05-18 JP JP6500408A patent/JPH08501280A/ja active Pending
- 1993-05-18 CA CA002136624A patent/CA2136624A1/en not_active Abandoned
- 1993-05-18 AU AU43591/93A patent/AU681853B2/en not_active Ceased
- 1993-05-18 DE DE69326064T patent/DE69326064T2/de not_active Expired - Fee Related
- 1993-05-18 DK DK93913627T patent/DK0643726T3/da active
- 1993-05-18 WO PCT/NL1993/000102 patent/WO1993024525A1/en not_active Ceased
1999
- 1999-11-19 GR GR990403009T patent/GR3031919T3/el unknown
2003
- 2003-07-09 JP JP2003194583A patent/JP2004123708A/ja active Pending

Also Published As

Publication number	Publication date
GR3031919T3 (en)	2000-03-31
DE69326064T2 (de)	2000-05-25
US5679641A (en)	1997-10-21
WO1993024525A1 (en)	1993-12-09
ATE183514T1 (de)	1999-09-15
CA2136624A1 (en)	1993-12-09
DE69326064D1 (de)	1999-09-23
ES2139012T3 (es)	2000-02-01
JPH08501280A (ja)	1996-02-13
EP0643726A1 (en)	1995-03-22
AU681853B2 (en)	1997-09-11
EP0643726B1 (en)	1999-08-18
AU4359193A (en)	1993-12-30
JP2004123708A (ja)	2004-04-22

Publication	Publication Date	Title
DK0643726T3 (da)	2000-03-20	Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
ATE415173T1 (de)	2008-12-15	Pan dr-bindeproteinen zur erhöhung der immunantwort
IL105554A0 (en)	1993-08-18	Peptides of human papilloma virus for use in human t cell response inducing compositions
TR199802423T2 (xx)	1999-02-22	Konsantre antikor terkibi.
DE69726426D1 (de)	2004-01-08	Unterdrückung von immunantwort durch hemmung von cathepsin s
DK0479948T3 (da)	1999-05-25	Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
DE69931482D1 (de)	2006-06-29	Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DK0633763T3 (da)	1997-12-29	Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
AU9363398A (en)	1999-04-27	Hepatitis c receptor protein cd81
NO952385L (no)	1995-06-22	Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen
BG103872A (en)	2000-07-31	Glycoconjugates of 20(s)-camptotecin
DE59508137D1 (de)	2000-05-11	Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
FR2724320B1 (fr)	1996-12-20	Nouvel implant pour le traitement des maladies acquises
PT723552E (pt)	2003-02-28	Oligopeptidos derivados de fragmentos de proteina reactiva c
TR199902866T2 (xx)	2000-02-21	Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
AU1318797A (en)	1997-08-20	Peptides and uses thereof for therapy of celiac diseases
TR199802387T2 (xx)	1999-03-22	Do�um kontrol� i�in kullan�lan Zona Pellucida proteinleri.
DE69529235D1 (de)	2003-01-30	Menschliche dnase i varianten
DK0938555T3 (da)	2005-05-23	Konstruktioner og komplekser af cyclin E
DE69836226D1 (de)	2006-11-30	Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
DK0999849T3 (da)	2003-01-06	Anvendelse af LBP til sepsisbehandling
BRPI0216042B8 (pt)	2021-05-25	polipeptídeo capaz de se ligar a ang-2, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso dos referidos polipeptídeos.